You are here: Industry Insights > Amgen

News List

Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies WorldPharmaNews
February 07, 2022
Amgen (NASDAQ:AMGN) and Plexium, Inc. (Plexium) today announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics...
Amgen and Arrakis Therapeutics announce multi-target collaboration to identify novel RNA degrader small molecule therapeutics WorldPharmaNews
January 13, 2022
Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas.
Amgen, Generate Biomedicines partner to create protein therapeutics pharmaceutical-business-review
January 07, 2022
Amgen has entered into a research collaboration agreement with Generate Biomedicines...
Amgen, Generate Biomedicines Enter Protein Therapeutics Pact contractphrma
January 06, 2022
Aims to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.
FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level Drugs
December 27, 2021
Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Amgen, Owkin Use AI to Improve Cardiovascular Risk Prediction contractpharma
December 17, 2021
Study demonstrates the ability of AI to improve the way clinicians predict patients' risk of suffering major cardiovascular events.
Amgen named to Dow Jones Sustainability World Index for eighth year EuropeanPharmaceuticalReview
December 01, 2021
Amgen has announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year. Amgen also was named to the DJSI North America Index for the ninth straight year.
The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director prnasia
August 12, 2021
Insilico Medicine, a global leader in end-to-end AI-powered drug discovery, announced the appointment of Steven Galson, MD, MPH as the independent member of the board of directors.
Amgen Investing $550M in New Biomanufacturing Facility contractpharma
August 06, 2021
Amgen has unveiled plans to build a new $550 million biologics manufacturing facility in Holly Springs, NC, creating 355 jobs along the way.
Amgen to set up $550m manufacturing plant in Holly Springs, US pharmaceutical-technology
August 05, 2021
Amgen is set to construct a new multi-product drug substance manufacturing facility in Holly Springs, North Carolina, with an investment of $550m.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page